CDx Diagnostics said results from a recent multicenter prospective trial show the use of its WATS3D test increases the detection of both Barrett’s esophagus and esophageal dysplasia by more than 80%. The results were published in the latest issue of United European Gastroenterology Journal and featured in the American Society for Gastrointestinal Endoscopy (ASGE’s) Scope Tech Talk Video Series.
The trial was conducted at 25 community-based gastrointestinal (GI) centers across the U.S. In the study, 4,203 patients were tested for esophageal disease. The findings show that with the inclusion of WATS3D overall detection of Barrett’s increased by 83%, while the detection of dysplasia increased by 88%. The study concludes that the sampling error can be improved dramatically with use of WATS3D.
Join us at the BIOMEDevice Boston Expo, April 18–19, 2018. Use promo code “MDDI” for 20% off conference registration and free expo access.
“There are a lot of technologies that only work in academic centers,” Mark Rutenberg, founder and CEO of CDx Diagnostics, told MD+DI. “A lot of things work in academia … but don’t work in a critical practice. WATS3D has been now shown to work extremely well in the academic settings and in the community practices. What this study shows is WATS3D works in the real world.”
The test received regulatory clearance in 2012 and was launched in 2014, Rutenberg said.
AbstractEndoscopic surveillance of Barrett ’s esophagus has become a foundation of the management of esophageal adenocarcinoma (EAC). Surveillance for Barrett’s esophagus commonly involves periodic upper endoscopy with biopsies of suspicious areas and random four-quadrant biopsies. However, targeted biopsies using narrow-band imaging can detect more dysplastic areas and thus reduce the number of biopsies required. Several specific mucosal and vascular patterns characteristic of Barrett’s esophagus have been described, but the proposed criteria are complex and diverse. Simpler classifications have recently…
I am so pleased to introduce this issue of Gastrointestinal Endoscopy Clinics of North America, “New Directions in Barrett’s Esophagus.” In terms of the morbidity and mortality associated with it, as well as the resources expended on it, Barrett’s esophagus (BE) and esophageal adenocarcinoma rank high in gastrointestinal (GI) maladies. Indeed, the question of how to manage the patient with chronic heartburn is probably second only to colorectal cancer screening as a public health concern in GI, and indications related to gastroesophageal reflux disease are routinely at or near the top the list for upper endoscopy.
When Barrett ’s esophagus (BE) is detected at the initial upper endoscopy (EGD), biopsies are obtained to confirm intestinal metaplasia but more importantly to rule out prevalent dysplasia/cancer. However, there is no clarity on the prevalence of high grade dysplasia / esophageal adenocarcinoma (HGD/EAC) among these patients on index endoscopy. Dysplasia detection rate (DDR) could be an important measure to ensure that a high quality examination is being performed.
CONCLUSION: Smoking and isoprostane levels were significantly associated with esophageal cancer in Zambians, but diet, HIV status, and alcohol consumption were not.
PMID: 26973419 [PubMed – in process]
Staging of patients with esophageal cancer includes a computed tomography (CT) scan of the chest, abdomen, and pelvis and an upper endoscopy with endoscopic ultrasound. Positron emission tomography (PET) CT has been increasingly used to rule out metastatic disease, detect recurrent disease after treatment, or predict the response to treatment. While PET CT is valuable in identifying metastatic and recurrent disease, its role in the initial staging of the disease is limited because it cannot reliably identify the T stage or invasion to locoregional lymph nodes. Furthermore, evidence supporting the role of PET CT in predicti…
CONCLUSIONS: Trousseau’s Syndrome must be considered in those presenting with recurrent strokes with an otherwise negative embolic work up especially in the elderly and those with cancer risk factors. It must prompt the clinician to look for an associated malignancy.Disclosure: Dr. JADEJA has nothing to disclose. Dr. Johnson has nothing to disclose. Dr. Soetanto has nothing to disclose. Dr. Nalleballe has nothing to disclose. Dr. DeNiro has nothing to disclose. Dr. Qureshi has nothing to disclose. Dr. Graber has received personal compensation for activities with Stemedica Inc., Novocure Inc., and Biogen Idec.
Esophageal adenocarcinoma (EAC) has increased dramatically in the past 3 decades, making its precursor lesion Barrett’s esophagus (BE) an important clinical problem. Effective interventions are available, but overall outcomes remain unchanged. Most of the BE population remains undiagnosed; most EACs are diagnosed late, and most BE patients will never progress to cancer. These epidemiologic factors make upper endoscopy an inefficient and ineffective strategy for BE diagnosis and risk stratification. In the current review, biomarkers for diagnosis, risk stratification, and predictors of response to therapy in BE are discussed.
Close and long-term surveillance by 24-hour pH monitoring and upper endoscopy is recommended in BE patients who undergo ARS to identify postoperative pathological reflux, and to early detect dysplasia or even adenocarcinoma. Further studies are requested to assess the molecular effects of ARS in dysplastic BE.
AimThe incidence of proximal gastric carcinoma (PGC) is rising worldwide for unknown reasons. Herein we investigated and compared the risk factors of early PGC with distal gastric carcinoma (DGC) in Chinese patients treated at a single tertiary hospital in China.
MethodsRisk factors of 379 consecutive surgically resected early gastric carcinomas (EGC) diagnosed with the 2010 WHO criteria were studied through review of medical records and upper endoscopy/biopsy findings, and interviews of patients and family members for demographics, history of environmental toxin exposure (ETE) and dietary habit, family and person…
e;a Y Rentería J
Esophageal cancer is a rare disease. In Spain, this tumor is the third most common gastrointestinal malignancy after colorectal and gastric cancer. Esophageal adenocarcinoma metastasizes to the skin with an incidence of 1 %, generally located in the neck, head and abdomen. It usually occurs in the overlying skin of the primary tumor, but may also appear in a distant site, the scalp being the most common place. Although the pathogenesis of esophageal adenocarcinoma is not well known, the existence of genetic alterations, such as the suppressor gene, has been proved and the involve…